Inspira Technologies Faces New Nasdaq Delisting Threat for Market Value Deficiency, Amends Debenture Terms
IINN sits 46% above its 52-week low of $0.403 on light trading volume (0.3× avg).
Summary
Inspira Technologies received a new Nasdaq delisting notice for market value deficiency, adding to its existing bid price issue, while also amending terms of a key convertible debenture.
Key Events · Corporate Governance and Compliance · IINN
-
New Nasdaq Delisting Notice
The company received a notification from Nasdaq on February 19, 2026, for failing to meet the minimum market value of publicly held shares (MVPHS) requirement of $35 million. This is a separate deficiency from the minimum bid price notice received on February 12, 2026. The company has 180 days, until August 18, 2026, to regain compliance.
-
Debenture Terms Amended
Inspira Technologies amended its senior convertible debenture with Bio-View Ltd., extending the deadline for certain prerequisites by 30 days to 75 days. The amendment also changed the source for a required $5 million investment, shifting from a previous agreement to investors introduced by Bio-View Ltd. via a placement agent agreement.
Analysis · IINN · Industrial Applications And Services
Inspira Technologies is now facing a second, distinct Nasdaq delisting threat for failing to maintain a minimum market value of publicly held shares of $35 million, compounding its existing bid price deficiency received on February 12, 2026. This significantly increases the risk of the company's shares being delisted. Additionally, an amendment to a senior convertible debenture with Bio-View Ltd. indicates delays and a change in the mechanism for securing a crucial $5 million investment, suggesting challenges in its financing efforts. Investors should monitor the company's progress on both Nasdaq compliance and its ability to secure the necessary funding.
At the time of this filing, IINN was trading at $0.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25.5M. The 52-week trading range was $0.40 to $1.65. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.